BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Male Hypogonadism readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Male Hypogonadism\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04049331-6672@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:testosterone undecanoate: Phase 2 readout est. (NCT04049331)
DESCRIPTION:testosterone undecanoate\, phase 2\, Hypogonadism.\nStudy: Test
 osterone Replacement in Male Cancer Survivors With Fatigue and Low Testost
 erone\nEstimated primary completion: 30 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04049331
URL:https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04798469-6672@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:testosterone undecanoate: Phase 2 readout est. (NCT04798469)
DESCRIPTION:testosterone undecanoate\, phase 2\, Hypogonadism.\nStudy: Pain
  Alleviation With Testosterone in Opioid-Induced Hypogonadism\nEstimated p
 rimary completion: 30 September 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/testosterone-undecanoate#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04798469
URL:https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
